Hey please help me diagnose a case of all from a senario
You give me a senario of all
I think there might be an overproduction of wbc lineage cells that's why rbc and platelet production are being hampered
In ALL, immature lymphoblasts (abnormal WBC precursors) proliferate uncontrollably and pack the bone marrow. This crowds out the normal stem cells, reducing production of:
- π΄ Red blood cells β anaemia (fatigue, pallor)
- π©Έ Platelets β thrombocytopenia (bruising, petechiae)
- π‘οΈ Normal WBCs β neutropenia (recurrent fevers/infections)
| Cytopenia | Mechanism | Symptom in Joshua |
|---|---|---|
| Anaemia | β RBC production | Pallor, fatigue |
| Thrombocytopenia | β Platelet production | Bruising, petechiae |
| Neutropenia | β Normal WBC production | Fever |
I will order a cbc first and in the smear i should be looking for immature wbc blast cells in excess of 30%
| Parameter | Result | Meaning |
|---|---|---|
| Hb | 6.8 g/dL β | Anaemia (marrow crowded out) |
| WBC | 45,000/ΞΌL β | Elevated (blasts spilling into blood) |
| Platelets | 28,000/ΞΌL β | Thrombocytopenia |
| Neutrophils | 0.4 Γ 10βΉ/L β | Neutropenia β explains the fevers |
π‘ Robbins Pathology notes: ALL presents with "symptoms relating to marrow replacement and pancytopenia" β exactly what you predicted!
I should do a bone marrow biopsy using flow cytometry markers i can distinguish
| Marker | B-ALL β | T-ALL | AML |
|---|---|---|---|
| TdT (terminal deoxytransferase) | β + | β + | β β |
| CD19 | β + | β β | β β |
| CD10 (CALLA) | β + | β β | β β |
| HLA-DR | β + | β β | +/β |
| CD7 | β β | β + | β β |
| Myeloperoxidase (MPO) | β β | β β | β + |
TdT is the master key β it's positive in ALL (both B and T), and negative in AML. MPO is the opposite.
β Quick Compendium of Clinical Pathology, 5th ed.: B-ALL blasts are positive for CD19, CD10, PAX5, CD34, CD99, HLA-DR, and nuclear TdT. Children with B-ALL have CR in >95% with therapy β excellent prognosis!
Philadelphia chromosome t(9:22)
| Feature | Detail |
|---|---|
| Translocation | t(9;22)(q34;q11) |
| Fusion gene created | BCR::ABL1 |
| Protein produced | Constitutively active tyrosine kinase β drives uncontrolled cell proliferation |
| Frequency in ALL | ~3% of children, ~25% of adults |
| Prognosis | High-risk / Poor β resists standard chemotherapy |
| Detection test | FISH (Fluorescence In Situ Hybridisation) or PCR |
β Goldman-Cecil Medicine: "Studies suggest that consolidation therapy including haematopoietic cell transplantation after initial chemotherapy improves overall survival compared with conventional chemotherapy alone, particularly for those who are Philadelphia chromosome-positive."
Give me the answer
β Washington Manual of Medical Therapeutics: "Treatment is subdivided into induction, consolidation, and maintenance phases, usually administered over a course of 2β3 years."
| Situation | Extra therapy |
|---|---|
| Ph+ (BCR-ABL1) | Add Imatinib/Dasatinib (TKI) |
| CD20+ blasts | Add Rituximab |
| Relapsed/refractory | CAR-T (Tisagenlecleucel) β approved up to age 25 |
| High-risk relapse | Allogeneic stem cell transplant |
| Step | Your Answer | Score |
|---|---|---|
| Mechanism (bone marrow failure) | β Correct | βββ |
| First-line investigation (CBC) | β Correct | βββ |
| Blast threshold | πΆ 30% β corrected to β₯20% (WHO) | ββ |
| Bone marrow biopsy + flow cytometry | β Correct | βββ |
| Philadelphia chromosome t(9;22) | β Perfect | βββ |
| Treatment phases | β Answered | βββ |